repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.
Company profile
Ticker
RGEN
Exchange
Website
CEO
Anthony Hunt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Repligen Sweden AB • Repligen GmbH • Repligen Singapore Pte. Ltd. • Repligen Europe B.V. • Repligen (Shanghai) Biotechnology Co. Ltd. • Repligen Japan LLC • Repligen India Private Limited • Repligen Korea Co., Ltd. • ARTeSYN Biosolutions Holdings Ireland Ltd. • ARTeSYN Biosolutions Ireland Limited ...
IRS number
42729386
RGEN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
1 Apr 24
DEFA14A
Additional proxy soliciting materials
1 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
8-K
Repligen Appoints Maggie A. Pax to Board of Directors
19 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
8-K
Entry into a Material Definitive Agreement
15 Dec 23
8-K
Unregistered Sales of Equity Securities
7 Dec 23
10-Q
2023 Q3
Quarterly report
31 Oct 23
8-K
Repligen Reports Third Quarter 2023 Financial Results
31 Oct 23
Transcripts
RGEN
Earnings call transcript
2023 Q4
21 Feb 24
RGEN
Earnings call transcript
2023 Q3
31 Oct 23
RGEN
Earnings call transcript
2023 Q2
2 Aug 23
RGEN
Earnings call transcript
2023 Q1
2 May 23
RGEN
Earnings call transcript
2022 Q4
22 Feb 23
RGEN
Earnings call transcript
2022 Q3
1 Nov 22
RGEN
Earnings call transcript
2022 Q2
2 Aug 22
RGEN
Earnings call transcript
2022 Q1
27 Apr 22
RGEN
Earnings call transcript
2021 Q4
17 Feb 22
RGEN
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
4.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 440 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 2.71 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Eddleman Roy T | 2.71 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | James Bylund | Common Stock | Payment of exercise | Dispose F | No | No | 182.95 | 444 | 81.23 k | 20,591 |
18 Mar 24 | Margaret Pax | Common Stock | Grant | Acquire A | No | No | 0 | 92 | 0.00 | 92 |
18 Mar 24 | Margaret Pax | Stock Option Common Stock | Grant | Acquire A | No | No | 194.25 | 2,236 | 434.34 k | 2,236 |
18 Mar 24 | Margaret Pax | Stock Option Common Stock | Grant | Acquire A | No | No | 194.25 | 195 | 37.88 k | 195 |
18 Mar 24 | Anthony Hunt | Common Stock | Gift | Dispose G | No | No | 0 | 2,000 | 0.00 | 183,249 |
11 Mar 24 | Ralf Kuriyel | Common Stock | Sell | Dispose S | No | No | 193.73 | 3,517 | 681.35 k | 24,260 |
11 Mar 24 | Ralf Kuriyel | Common Stock | Option exercise | Acquire M | No | No | 86.1 | 1,271 | 109.43 k | 27,777 |
11 Mar 24 | Ralf Kuriyel | Stock Option Common Stock | Option exercise | Acquire M | No | No | 86.1 | 1,271 | 109.43 k | 0 |
News
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
25 Mar 24
What's Going On With Life Science-Focused Repligen Stock Today?
21 Feb 24
Repligen Q4 Adjusted EPS $0.33, Inline, Sales $155.74M Beat $155.39M Estimate
21 Feb 24
Earnings Scheduled For February 21, 2024
21 Feb 24
Keybanc Maintains Overweight on Repligen, Raises Price Target to $220
15 Feb 24